A number of genomic assays such as MammaPrint [33], Oncotype DX [34], and EndoPredict [35] have been shown to offer clear prognostic value, aiding in the selection of appropriate adjuvant chemotherapy regimens in early-stage BC patients with ER+ HER2− disease that have 0–3 positive ALNs. Here, ERBB2 is linked to breast cancer.